The U.S. Supreme Court’s ruling last week that naturally occurring human genes cannot be patented is believed to help advance the push of technology toward greater affordability and help drive costs lower.
The ABPI has called for the NHS to provide more data on the uptake and access to new medicines in the UK. This follows the second publication of the NHS’s ‘Innovation Scorecard,’ a measure of how quickly different NHS trusts are adopting the latest NICE-approved treatments and drugs.
A US Congressman has introduced legislation requiring study results of all clinical trials – positive and negative – to be registered at ClinicalTrials.gov, with failure to comply resulting in loss of eligibility for grants.
GlaxoSmithKline dismisses Jingwu Zang, senior VP and head of R&D in Shanghai, one of key authors of a paper based on fabricated data, about the role of a protein called interleukin-7 in autoimmune disease.
A new initiative which aims for “a world free of cancer by 2050” has been launched in the US, stressing the need for more patient-centred innovation and an appreciation of the economic benefits of new cancer drugs.
Ben Steele talks with Sarah Garner, Associate Director of R&D at NICE, about the rising cost of pharma R&D, and how NICE plans to combat this trend by examining the role of real world data in reducing the costs of innovation.